By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher today said that its board of directors has authorized a plan to repurchase $750 million of the firm's common stock.

The one-year plan would involve the firm acquiring shares of its common stock on the open market or in negotiated transactions.

Thermo Fisher said that it will offer approximately $750 million of senior notes to refinance outstanding indebtedness.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.